Nextferm Technologies Ltd. · TASE:NXFR.M
Nextferm Technologies — Investor Presentation (November 2022)
25 slides from Nextferm Technologies's investor presentation, November 2022
Slide 1: NextFerm Technologies: Leading The Alternative Protein Revolution
NEXTFERM TECHNOLOGIES Leading The Alternative Protein Revolution November 2022 TASE: NXFR
Slide 2: Disclaimer
This presentation is intended for the provision of non-comprehensive information for the sake of convenience solely. You are hereby referred to the full prospectus and immediate and periodic reports filed by the company with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. for DI
Slide 3: About NextFerm: Leading the Alternative Protein Revolution
ABOUT NEXTFERM: LEADING THE ALTERNATIVE PROTEIN REVOLUTION Experienced Team in the Food and Food-tech Industry Breakthrough Technology for Innovative Yeast-based Proteins and Nutrients ProteVin™ Revolutionary Vegan Protein Launched in June 2022 (USA) • Yeast Derived • Animal-like Nutritional Value •
Slide 4: ProteVin - Commercial Status
ProteVin™ - COMMERCIAL STATUS First launched - June 2022 ~ 100 Companies 6 Purchase Orders 10 Pilots Above $3M POs & evaluating ProteVin™ 4 Territories Supply Agreement 8.5 Tons supplied 4
Slide 5: Launched in the USA by Spacemilk Using ProteVin brand
Launched in the USA by Spacemilk Using ProteVin™ brand Launched expected December 2022. Available for preorder at Spacemilk’s website: https://spacemilk-smk.myshopify.com/products/pre-order-spacemilk 5
Slide 6: About NextFerm – The Team
ABOUT NEXTFERM – THE TEAM Experienced Team in the Food and Food-tech Industries Company management is comprised of former Senior Management of Enzymotec, which developed innovative ingredients within the world of nutrition. Enzymotec reached revenues of over $80M and went public (NASDAQ) during 2013
Slide 7: Experienced Management Team in the World of Nutrition
EXPERIENCED MANAGEMENT TEAM IN THE WORLD OF NUTRITION Yossi Ohana, CFO Boaz Noy, CEO and Director Yossi Peled, Chairman Former VP Finance of Enzymotec Former Sr. VP and Head of the BioActive Former Chairman and board member of Ingredients Division at Enzymotec Enzymotec and Former CEO of Galam Yoni
Slide 8: Breakthrough Technology
BREAKTHROUGH TECHNOLOGY FOR PRODUCING YEAST-DERIVED, INNOVATIVE, FUNCTIONAL VEGAN FOOD INGREDIENTS Yeast Improvement Fermentation Separation & Scale-up (Patented, Non-GMO) (Cost-effective) Purification (from Lab to Industry) Improvement of yeast Process optimization for Development of efficient Impl
Slide 9: The only fermented vegan protein with animal like nutritional value
The only fermented vegan protein with animal like nutritional value and neutral taste 9
Slide 10: Why Vegan Protein
THE WORLD GOES VEGAN DUE TO THREE REASONS: WHY Health Compassion Sustainability VEGAN Plant based diet is healthier Decrease animal suffering Securing world natural resources PROTEIN The growing shift towards vegan nutrition creates an increase in the need for vegan protein sources with better nutri
Slide 11: Alternative Finished Products Market Expected to Grow to $290B Till 2035
ALTERNATIVE FINISHED PRODUCTS MARKET IS EXPECTED TO GROW TO $290B TILL 2035 (*) An Analysis by BCG and Blue Horizon : “Every Tenth Portion of Meat, Eggs, Dairy, and Seafood Eaten Around the Globe Will Be Made from Alternative Proteins by 2035” Expected alternative market growth 350 300 $290B (**) 25
Slide 12: Will Lead The Booming Vegan Protein Market
Will Lead The BOOMING Vegan Protein Market 12
Slide 13: ProteVin - Disruptive Value Proposition
PROTEVIN™- DISRUPTIVE VALUE PROPOSITION YEAST DERIVED NON-GMO VEGAN PROTEIN PRODUCED THROUGH INNOVATIVE FERMENTATION PROCESSES Animal-like nutritional value: • High level of Essential Amino Acids (53% EAA), Branched Amino Acids (21% BCAA) and 9% Leucine • Highly digestible protein (PDCAST=1) Neutral
Slide 14: The Leading Alternative Protein
Pea & Rice Protein Source ProteVin™ Whey Soy Blend Vegan Source + - + + Allergen Free / No impurities + - - - The leading + - - + alternative protein Sustainability Taste & Flavor + + + - Amino Acid Composition (AA) + + - - High Digestibility + + + - 14
Slide 15: Evaluation responses from food and supplement companies
Evaluation responds from food and dietary supplement Works great with companies, who are powders examining the integration of ProteVin™ in their products Works great with Works great with meat analogs Vegan Yogurt Stable in Works great with sterilization fruits drinks process of up to 110C 15
Slide 16: ProteVin: Operational Plan
PROTEVIN™: OPERATIONAL PLAN H2 DEC H1 DEC H2 DEC H2 DEC 2022 2021 2022 2022 2022 2022 2022 2023 Initial production setup Commercial Launch Growth 1 Starting EU production Initial Set-up of production Commercial launch and initial supply A manufacturing agreement Commercial profitable by subcontracto
Slide 17: ProteVin Key Goals for 2022
PROTEVIN™ Operation of first manufacturing facility: With a capacity of tens of tons KEY GOALS for 2022, GFR Canada - Achieved FOR 2022 Launch in USA: Starting supplying first orders - Achieved Growing market demands: Additional orders, accelerating growth into sports nutrition and food markets by d
Slide 18: Milestones & Target Markets
MILESTONES & TARGET MARKETS 2021 Achievements Key goals 2022 ProteVin™ market expansion to new segments and territories Industrial Scale Commissioning of GFR Pilot Completed initial production line Dairy Infant Well-being substitutes Nutrition Commercial Launch First POs from US Customers Creating D
Slide 19: Astaxanthin Yeast-Based Antioxidant
ASTAXANTHIN YEAST-BASED ANTIOXIDANT The only astaxanthin without taste or odor unlike alga based astaxanthin Offred as: • Gummies • Oil for soft-gels • Cold water dispersible powder Launched in USA & Canada 19
Slide 20: Patents and Regulation
PATENTS AND REGULATION NextFreeze™ Astaferm® ProteVin™ Patents EU: Granted for strain PCT filed for Strain Process patent was filed Russia: Granted for strain and for process composition Strain patent was filed Under evaluation in additional territories Open for marketing in the US Open for marketin
Slide 21: ProteVin - Trade Shows 2022
PROTEVIN - TRADE SHOWS 2022 April 2022, Cologne July 2022 Chicago October 2022 October 2022, Las Vegas November 2022, TLV December 2022, Paris Germany USA Singapore USA Israel France Innovation for Food and beverage Food and beverage Dietary supplements Food innovation Food and beverage Food and bev
Slide 22: Financial Information
FINANCIAL INFORMATION $31M Raised (2014-2021) Private Placement (December 2021): Raised $8M Market TASE IPO (January 2021): Raised $11M, Market cap of $33M Former Equity Rounds (Private investments): Raised $12M B2C 2021 Cash & Cash equivalents as of September 30, 2022: ~ $5.4M The Cash will serve t
Slide 23: Financial Information
FINANCIAL INFORMATION USD in thousands 9M 2022 9M 2021 2021 2020 STATEMENT OF OPERATION Net Revenues 198 141 242 95 Gross (Loss) Profit (**) (296) 6 23 19 Market Operating Loss (5,591) (3,243) (4,467) (3,056) B2C Adjusted EBITDA2021 (*) (4,996) (2,962) (4,113) (2,635) BALANCE SHEET Cash, cash equiva
Slide 24: NextFerm - Summary
NextFerm - Summary Winning Alternative protein- Leading value proposition technology booming market in the global alternative platform protein market Experienced team Game changing a vegan protein with neutral taste & animal like nutritional value 24 24
Slide 25: Thank You!
THANK YOU! For more information: [email protected] www.nextferm.com
NextFerm Technologies — Investor Presentation (November 2022) on 6ix